Radiology and Oncology

More info: https://lnkd.in/dd9aFbMC

💡 Recharged and ready for 2025? Start the year with a dive into cutting-edge clinical practice! In our newest Radiology and Oncology publication, we present the Current Operating Procedure (COP) for Bleomycin ElectroScleroTherapy (BEST), a cutting-edge approach for managing low-flow vascular malformations. Perfect as “light” post-holiday reading to get back into full working mode! Read the full article here: https://lnkd.in/dhpC7SZ9

🎄As the year comes to a close, we would like to thank all our readers, authors, and collaborators for their continued support and dedication to advancing science. This year has been filled with remarkable research and progress, and we look forward to bringing you even more cutting-edge studies and initiatives in 2025. We wish you a joyful holiday season and a successful New Year! Warm regards, The Radiology and Oncology Team

🗞 A Glimpse into the Past: Radiology Advertisements in 1972 🗞 As we look back at the 1972 issues of our Radiology and Oncology journal, the advertisements tell an intriguing story of that time. The pages were filled with ads for contrast agents from both domestic pharmaceutical companies, like Krka, and international, such as Bracco from Milan. One of the prominent contrast agents advertised was Iodamide, a groundbreaking iodine-based medium used in X-ray imaging. Back then, ionic high-osmolality contrast agents like Iodamide were the standard, helping radiologists visualize anatomical structures with remarkable precision for that era. ✨ Fun Fact: In the 1970s, ionic contrast agents dominated the field but often caused discomfort and side effects due to their high osmolality. This eventually led to the development of non-ionic, low-osmolality contrast agents in the 1980s, which significantly improved patient safety and comfort. 🔍 Then vs. Now: 1972: Ionic high-osmolality agents like Iodamide were the go-to options. Today: Modern contrast media, such as non-ionic agents like Iohexol (Omnipaque) and Iopamidol (Isovue), are widely used due to their enhanced safety profiles and reduced adverse effects. 📜 Do you have memories or stories of early contrast agent usage? Share them with us below! #RadiologyAndOncology

📢 We are pleased to share that our journal has been featured in a special brochure prepared by Sciendo, highlighting journals that have achieved an Impact Factor. The brochure provides an overview of key statistics and accomplishments, reflecting the collective effort of our editorial team, authors, and reviewers. You are welcome to explore the full brochure here: Impact Factor Catalogue 2024.pdf (https://lnkd.in/gyE7n3az)

🌟 Exploring the Future of AI in Radiology and Oncology🌟 Last week, our editorial board at the journal *Radiology and Oncology* convened to discuss one of the hottest topics in science and publishing—how AI, specifically ChatGPT, can reshape the way we work, research, and communicate. As AI becomes an increasingly prominent tool in medicine, it opens doors to new possibilities for research, collaboration, and education. Imagine a future where AI helps us interpret imaging data faster, facilitates personalized treatments, and accelerates discoveries. Of course, the conversation wasn’t without its debates. Can we trust AI to generate content at the level of human experts? What are the ethical implications of relying on technology for insights? Some voiced concerns about AI overtaking human judgment, while others highlighted its role as a supportive tool, one that complements our work, not replaces it. But here’s the twist—this post you’re reading now wasn’t written by a human editor. It was actually created by the very tool we were discussing during our meeting… Me! ChatGPT. 🤖✨ I’ve been a quiet observer during these conversations, and now, I'm part of them. So, the question remains—will AI become a trusted colleague in our field or just another tool in the box????

🎓 40 YEARS 🎓 It all started when professor Gregor Sersa and I were exploring the archives of Radiology and Oncology in search of interesting historical details. As we went through the older volumes, a question arose: how many years has Professor Serša actually been involved with the journal? For those who may not know, Professor Serša is the current editor-in-chief of Radiology and Oncology, and I was curious to discover when his journey with the journal began. 👩💻 We began reviewing multiple issues, tracing back through the years until we finally found the answer. His name first appeared in the journal in 1984 as part of the editorial staff. That means this year, 2024, marks his 40th anniversary with Radiology and Oncology! 🎉 This is an extraordinary milestone that not only highlights his long-standing dedication but also his significant contributions to the journal over four decades. 👏 Professor Serša’s work has been crucial in shaping the journal’s reputation and impact in the field of oncology and radiology. As both a researcher and an editor, he has tirelessly worked to ensure that Radiology and Oncology remains a vital platform for scientific innovation and collaboration. His leadership has influenced countless projects, fostered new ideas, and maintained the highest standards of academic excellence. 🎓 We are honored to celebrate this incredible achievement and offer our deepest congratulations to Professor Gregor Sersa. His 40 years of commitment have not only enriched the journal but have also significantly advanced the field as a whole. 🔬 ( In the picture, you can see Professor Serša holding the original collection of all issues from 1984.)

🔍 Question of the Day: Today, we received an inquiry about how often our journal, Radiology and Oncology, is published. We are pleased to share that we release new issues four times a year, a practice we have maintained for many years now! 📅 For those interested in exploring our history, you can access issues up until the very first issue from 2001 on our website. Dive into the advancements and contributions in the field over the years! Thank you for your continued interest in our journal. If you have more questions, feel free to reach out!

📝 Inspiring Workshop & Roundtable Discussion on Scientific Publishing 📝 Last week, we had the honor of organizing an engaging #workshop at the University of Ljubljana headquarters, where experts from both national and international journals came together for a #roundtable discussion on a highly relevant topic: “The importance and challenges of local publication of an international scientific journal at the University: possibilities for cooperation between journals from related fields, impact on the quality and development of studies, research, and profession.” We were fortunate to have a distinguished panel of #editors sharing their valuable insights, including: Prof. Gregor Sersa (Radiology and Oncology) Asist.-researcher Maša Čater, PhD (Slovenian Neuroscience journal eSinapsa, SiNAPSA) Prof. Svjetlana Kalanj Bognar (Croatian Medical Journal) Prof. John Kastelic (Canadian Veterinary Journal) The discussion focused on how we can improve collaboration between related journals, the unique challenges local journals face in maintaining international relevance, and the profound impact such #publications have on advancing research and professional #development. It was a privilege to be a part of this meaningful exchange of ideas that will surely influence the future of scientific #publishing. A huge thank you to all the speakers and participants for making this event a success! Looking forward to more collaborations and shared knowledge in the future. 🙌 #ScientificPublishing #InternationalJournals #CollaborativeScience #ResearchImpact #AcademicPublishing #medicine #veterinarymedicine #science

This week, we would like to spotlight a prospective study by Nezka Hribernik, exploring the role of quantitative imaging biomarkers in early FDG-PET/CT for detecting immune-related adverse events in melanoma patients. https://lnkd.in/ddcENW9F Stay tuned for more groundbreaking research! 📃 https://lnkd.in/dR5CWBPc